IPN Ipsen SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Attachment



EN
19/02/2026

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen showcases transformative potential of early immuno-oncology pipe...

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor typesPreclinical data show potential of Ipsen’s growing collection of investigational medicines, leveraging precision immuno‑modulation to deliver differentiated anti‑tumor activity PARIS, FRANCE, 18 ...

March 18, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen présente le potentiel transformateur de son pipeline d’immuno on...

Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en charge des tumeurs solides.ITGA2 identifié comme nouvelle cible de l’anticorps-conjugué (ADC) innovant IPN60300 d’Ipsen, fortement surexprimée dans de nombreux types de tumeurs solides.Ces données précliniques illustrent le potentiel croissant du portefeuille de médicaments expé...

March 18, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - February 2026 - Monthly information relative to the total numb...

Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of ...

March 13, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - Février 2026 - Information mensuelle relative au nombre total ...

Ipsen - Février 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital social Nombre total de droits de vote (1) 28 février 2...

March 13, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen appoints Michelle C. Werner as EVP, President of North America

Ipsen appoints Michelle C. Werner as EVP, President of North America PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “I am very pleased to welcome Michelle to Ipsen and to the Executive Leadership Team. She brings a wealth of experience in leading teams both in the U.S. and around the world and has...

March 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch